A practical reference on peptide mapping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-11. Anything still debated is marked as such rather than presented as settled.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
About 89 percent of the bank's $172 billion in deposit liabilities exceeded the maximum insured by the FDIC. Two days after the failure, the FDIC received exceptional authority from the Treasury and announced jointly with other agencies that all depositors would have full access to their funds the next morning. Seeking to auction off all or parts of the bank, the FDIC reopened it on Monday March 13 as a newly organized bridge bank, Silicon Valley Bridge Bank, N.A. Although some characterized the government response as a bailout, the plan did not entail rescuing the bank, its management or shareholders, but rather making uninsured depositors whole from the proceeds of selling the bank's assets, without the use of taxpayer money. The collapse of SVB had significant consequences for startup companies in the U.S. and abroad, with many briefly unable to withdraw money from the bank. Other large technology companies, media companies, and wineries were also affected. For a number of founders and their venture capital backers, this was the bank of choice.
==== Record GDP growth ==== At the end of 2023, Brazil once again became one of the ten largest economies in the world, according to the IMF, the country had dropped out of the ranking between 2019 and 2022, when it fell to 13th place. Also at the end of 2023, the Brazilian trade balance marked the largest surplus in its history, with 98 billion dollars, a significant jump in relation to the 2022 surplus, of 61 billion dollars, which was the previous record. This increase was sustained by the 1.7% increase in exports and the 11.7% drop in imports, resulting from the 8.8% decline in the price of imported items, such as fertilizers, whose price decreased by 44.9% in comparison with 2022. The current account showed a deficit of 28 billion dollars in 2023 and direct investment in the country totaled 62 billion dollars. Released on 1 March 2024, Brazil's GDP grew 2.9% in the first year of the Lula government. The increase was driven especially by the super harvest in the agricultural sector, the recovery of the services sector and the job market, the maintenance of social spending, and the expansion of fiscal space opened by the New Fiscal Framework; growth surpassed the first year of the Bolsonaro, Temer, Dilma 2, Lula 1 and FHC 2 governments, being lower only than the first year of the Dilma 1, Lula 2 and FHC 1 governments.
SR-16435 is a drug which acts as a potent partial agonist at both the μ-opioid receptor and nociceptin receptor. In animal studies it was found to be a potent analgesic, with results suggestive of reduced development of tolerance and increased activity against neuropathic pain compared to classic μ-selective agonists.
== Symmetry == During the 19th century crystallography was progressively transformed into an empirical and mathematical science by the adoption of symmetry concepts. In 1832 Franz Ernst Neumann used symmetry considerations when studying double refraction in crystals. Woldemar Voigt, who was a student of Neumann, in 1885 formalized Neumann's principle as "if a crystal is invariant with respect to certain symmetry operations, any of its physical properties must also be invariant with respect to the same symmetry operations". Neumann's principle is sometimes referred to as the Neumann–Minnigerode–Curie principle based on later work by Bernhard Minnigerode (another student of Neumann) and Pierre Curie. Curie's principle "the symmetries of the causes are to be found in the effects" is a generalization of Neumann's principle. The relations between symmetry and physical and chemical properties were established throughout the 19th century: the notion of hemihedry (Weiss, 1819; Delafosse, 1840), the 7 crystal systems (Mohs, 1822), the notion of point lattice (Seeber, 1824), the 32 crystal classes (Frankenheim, 1826; Hessel, 1830; Gadolin, 1869), molecular chirality (Pasteur, 1848), the 14 Bravais lattices (Bravais, 1850), the 65 chiral groups that contain only proper symmetry operations – rotations, translations and roto-translations (Sohncke 1879), and, finally, the 230 space groups (Fedorov, 1891; Schoenflies, 1891; Barlow, 1894).
Sources: en.wikipedia.org
By September 1900, the British were nominally in control of both Republics, with the exception of north Transvaal. However, they discovered they only controlled the territory their columns physically occupied. Despite the loss of their capitals and half their army, the Boer commanders adopted guerrilla warfare, conducting raids against railways, resource and supply targets, aimed at disrupting the operational capacity of the British Army. They avoided pitched battles and casualties were light. Boer commando units were sent to the district from which its members were recruited, which meant they could rely on local support and knowledge of the terrain and towns, enabling them to live off the land. Their orders were simply to act against the British whenever possible. Their tactics were to strike fast causing as much damage as possible, then withdraw before enemy reinforcements could arrive. The vast distances of the republics allowed Boer commandos freedom to move about and made it nearly impossible for the 250,000 British troops to control the territory effectively using columns alone. As soon as a British column left a town or district, British control of that area faded away. Boer commandos were especially effective during the initial guerrilla phase because Roberts had assumed the war would end with the capture of the capitals and dispersal of the Boer armies. British troops were therefore redeployed out of the area, and had been replaced by lower-quality Imperial Yeomanry and locally-raised irregular corps.
Moreover, various protocols and methods of analyzing IDPs, such as studies based on quantitative analysis of GC content in genes and their respective chromosomal bands, have been used to understand functional IDP segments.
==== Cavity prevention ==== Nano-hydroxyapatite possesses a remineralising effect on teeth and can be used to prevent damage from carious attacks. In the event of an acid attack by cariogenic bacteria, nano-hydroxyapatite particles can infiltrate pores on the tooth surface to form a protective layer. Furthermore, nano-hydroxyapatite may have the capacity to reverse damage from carious assaults by either directly replacing deteriorated surface minerals or acting as a binding agent for lost ions. In some toothpaste hydroxyapatite can be found in the form of nanocrystals (as these are easily dissolved). In recent years, hydroxyapatite nanocrystals (nHA) have been used in toothpaste to combat dental hypersensitivity. They aid in the repair and remineralisation of the enamel, thus helping to prevent tooth sensitivity. Tooth enamel can become demineralised due to various factors, including acidic erosion and dental caries. If left untreated this can lead to the exposure of dentin and subsequent exposure of the dental pulp. In various studies the use of nano hydroxyapatite in toothpaste showed positive results in aiding the remineralisation of dental enamel. In addition to remineralisation, in vitro studies have shown that toothpastes containing nano-hydroxyapatite have the potential to reduce biofilm formation on both tooth enamel and resin-based composite surfaces.
Sources: en.wikipedia.org
==== Adverse effects ==== The most common adverse effects of nabilone include drowsiness, dizziness, dry mouth, euphoria, concentration difficulties, ataxia, and headache. It has the potential to affect the central nervous system, resulting in anxiety, disorientation, depression, hallucinations and psychosis. Moreover, it may lead to cardiovascular side effects such as orthostatic hypotension and tachycardia. Gastrointestinal adverse reactions also include anorexia, constipation, nausea, vomiting, and oral paresthesia (sensation of tingling in the mouth).
=== Cough === For chronic and acute coughs, a Cochrane review found no strong evidence for or against the use of honey. For treating children, the systematic review concluded with moderate to low evidence that honey helps more than no treatment, diphenhydramine, and placebo at giving relief from coughing. Honey does not appear to work better than dextromethorphan at relieving coughing in children. Other reviews have also supported the use of honey for treating children. The UK Medicines and Healthcare products Regulatory Agency recommends avoiding giving over-the-counter cough and common cold medication to children under six, and suggests "a homemade remedy containing honey and lemon is likely to be just as useful and safer to take", but warns that honey should not be given to babies because of the risk of infant botulism. The World Health Organization recommends honey as a treatment for coughs and sore throats, including for children, stating that no reason exists to believe it is less effective than a commercial remedy.
== Ownership and finance == Marks and Hazan initially supported GYG with their own money. In 2009, they sold a minority stake to Peter Ritchie, Guy Russo and Steve Jermyn, who had previously been involved with McDonald's Australia. Russo was subsequently appointed chairman of the board. The board also includes co-founder Robert Hazan, Tom Cowan of TDM Growth Partners, Rokt CEO Bruce Buchanan, and three former McDonalds executives. Investment firm TDM Growth Partners bought a stake in the company for $44 million in August 2018. In December 2020, the publicly listed Magellan Financial Group bought 10% of the company for $86.8 million. In May 2022, Magellan sold its 11.6% stake in the company to an entity owned by investment bank Barrenjoey Capital Partners for $140 million. Marks stated in 2019 that his goal was to list GYG on the Australian Securities Exchange. In 2020, he stated that he was also ambitious to expand the company's presence in the United States, citing Australia's "antiquated" labour laws, high rents, and expensive fresh produce. Marks resigned as CEO due to a health scare in May 2023, but he changed his mind and remained. Hilton Brett was appointed co-CEO in October 2023. GYG was listed on the Australian Securities Exchange on 20 June 2024.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.